Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.

You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...

The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...